Formula (I) Lung Composition with Surfactant for BPD Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel compositions and methods to prevent or treat neonatal lung injury, bronchopulmonary dysplasia (BPD), and BPD-associated pulmonary hypertension (BPD-PH), as existing treatments are ineffective and carry significant risks or uncertainties, particularly in premature infants.
Innovation Solution
A composition comprising a compound of formula (I) or its stereoisomer, enantiomer, tautomer, or pharmaceutically acceptable salt, formulated for various administration routes, including intravenous, pulmonary, and inhalation, which inhibits inflammation and modulates macrophages to protect lung tissue, combined with a lung surfactant to treat BPD and BPD-PH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments (inhaled budesonide, budesonide-surfactant combination, mother's milk, intramuscular vitamin A, prophylactic hydrocortisone) are used to prevent BPD, then the rate of BPD is modestly reduced, but the disease is not cured and the treatments carry significant risks or uncertainties
Solution Approach 1:
The patent changes the chemical parameters by using a novel compound of formula (I) with specific molecular structures (where n=0-5, X=NH/O/S/CH2, Y=Phenyl with substituents, Z=NH/O/S/CH2/none, R=H/C(O)R2/SO2R2, R1=H/C(O)R2/SO2R2, R2=Ethyl/methyl/isopropyl/n-propyl/t-butyl/n-butyl/NH2/NR3R4) that differ fundamentally from existing treatments. This new chemical class allows for different mechanism of action and risk profiles while aiming for superior efficacy in preventing BPD and BPD-PH.
Solution Approach 2:
The patent combines the novel compound of formula (I) with lung surfactant in a composite therapeutic composition. This combination addresses multiple aspects of BPD pathogenesis simultaneously - the compound targets inflammatory and vascular mechanisms while the surfactant addresses surfactant deficiency and alveolar stability, creating a synergistic effect that overcomes the limitations of single-agent treatments.
2Reliability
If medications targeting the nitric oxide signaling pathway (NO inhalation, oral sildenafil citrate) are used to treat BPD-PH, then some improvement is suggested from animal and clinical studies, but the medications have not been specifically approved for this indication and pathogenesis is poorly understood
Solution Approach 1:
The patent introduces a novel compound of formula (I) that represents a new pharmacological class for BPD-PH treatment. The molecular structure parameters (n=0-5, various X, Y, Z, R, R1, R2 groups) allow for optimization of pharmacokinetic and pharmacodynamic properties, potentially offering superior efficacy and safety compared to existing NO pathway medications that lack specific approval for this indication.
Solution Approach 2:
The novel compound of formula (I) acts as an intermediary agent that may modulate multiple pathways involved in BPD-PH pathogenesis. By developing a new mechanism of action rather than relying on existing NO pathway medications, the patent creates a bridge between understanding the complex pathogenesis and providing effective, approved treatment.
3Reliability
If a novel compound of formula (I) is used to prevent BPD and BPD-PH, then significant improvements in lung morphology, cell proliferation, and vascular development are demonstrated, but the compound requires formulation for multiple administration routes and combination with surfactant
Solution Approach 1:
The patent designs the novel compound of formula (I) with versatile pharmacological properties that allow it to be effective across multiple administration routes (intravenous, inhalation, enteral, topical, oral). The molecular structure parameters (n=0-5, various substituents) are optimized to provide bioavailability and efficacy regardless of the route, making the treatment adaptable to different clinical scenarios and patient needs.
Solution Approach 2:
The patent merges the novel compound of formula (I) with lung surfactant in a unified therapeutic composition. This combination consolidates multiple mechanisms of action into a single administered preparation, simplifying the treatment approach while maintaining comprehensive coverage of BPD and BPD-PH pathogenesis. The formulation combines the compound and surfactant in compatible excipients for coordinated delivery to the lung.
Data Source
AI summary
The present invention includes a composition and method for preventing at least one of: neonatal lung injury, bronchopulmonary dysplasia (BPD), or BPD-associated pulmonary hypertension (BPD-PH) comprising: a compound of formula (I) and variants thereof:in an amount sufficient to prevent at least one of: neonatal lung injury, bronchopulmonary dysplasia (BPD), or BPD-associated pulmonary hypertension (BPD-PH).